<?xml version='1.0' encoding='utf-8'?>
<document id="28575767"><sentence text="Lacosamide and concomitant use of antiepileptic and other medications in a US population - A retrospective cohort study."><entity charOffset="0-10" id="DDI-PubMed.28575767.s1.e0" text="Lacosamide" /></sentence><sentence text="Information on the use of lacosamide and concomitant antiepileptic and non-antiepileptic drugs (non-AEDs) is available from clinical trials and observational studies with small sample sizes"><entity charOffset="26-36" id="DDI-PubMed.28575767.s2.e0" text="lacosamide" /></sentence><sentence text=" This retrospective cohort study was conducted to gain insight into the use of lacosamide in a large number of patients with epilepsy in real-life clinical practice with less restrictive selection criteria compared with clinical trial participants"><entity charOffset="79-89" id="DDI-PubMed.28575767.s3.e0" text="lacosamide" /></sentence><sentence text=" The Truven Health MarketScan (Commercial Claims and Medicare Supplemental) database was used to identify patients with a prior diagnosis of epilepsy with at least one prescription claim for lacosamide between June 2009 and September 2013 and continuous health insurance enrolment with medical and pharmacy coverage during the 1-year pre-index baseline period"><entity charOffset="191-201" id="DDI-PubMed.28575767.s4.e0" text="lacosamide" /></sentence><sentence text=" A total of 8859 eligible patients were identified, of whom, at index (lacosamide initiation), 16"><entity charOffset="71-81" id="DDI-PubMed.28575767.s5.e0" text="lacosamide" /></sentence><sentence text="8% received lacosamide as monotherapy and 54"><entity charOffset="12-22" id="DDI-PubMed.28575767.s6.e0" text="lacosamide" /></sentence><sentence text="0% as polytherapy" /><sentence text=" The median prescription duration was 196days (Interquartile range 69-476days)" /><sentence text=" Levetiracetam was the most frequently prescribed concomitant AED across all age groups, followed by phenytoin among older (&gt;65years) and lamotrigine among younger patients"><entity charOffset="1-14" id="DDI-PubMed.28575767.s9.e0" text="Levetiracetam" /><entity charOffset="101-110" id="DDI-PubMed.28575767.s9.e1" text="phenytoin" /><entity charOffset="138-149" id="DDI-PubMed.28575767.s9.e2" text="lamotrigine" /><pair ddi="false" e1="DDI-PubMed.28575767.s9.e0" e2="DDI-PubMed.28575767.s9.e0" /><pair ddi="false" e1="DDI-PubMed.28575767.s9.e0" e2="DDI-PubMed.28575767.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28575767.s9.e0" e2="DDI-PubMed.28575767.s9.e2" /><pair ddi="false" e1="DDI-PubMed.28575767.s9.e1" e2="DDI-PubMed.28575767.s9.e1" /><pair ddi="false" e1="DDI-PubMed.28575767.s9.e1" e2="DDI-PubMed.28575767.s9.e2" /></sentence><sentence text=" Older patients who had LCM monotherapy at initiation, were prescribed fewer concomitant AEDs, but more non-AEDs" /><sentence text=" The most common non-AED medications were prescribed for pain, psychiatric conditions, hyperlipidemia and gastrointestinal diseases across all age groups" /><sentence text=" Overall, results suggest that the lacosamide use is driven predominantly by age and that there is substantial use of lacosamide monotherapy (16"><entity charOffset="35-45" id="DDI-PubMed.28575767.s12.e0" text="lacosamide" /><entity charOffset="118-128" id="DDI-PubMed.28575767.s12.e1" text="lacosamide" /><pair ddi="false" e1="DDI-PubMed.28575767.s12.e0" e2="DDI-PubMed.28575767.s12.e0" /><pair ddi="false" e1="DDI-PubMed.28575767.s12.e0" e2="DDI-PubMed.28575767.s12.e1" /></sentence><sentence text="8%), despite lack of indication at the time of the study" /><sentence text=" Results also reveal substantial use of concomitant non-AEDs; 90" /><sentence text="4% among patients &gt;65years of age and 54" /><sentence text="3% among those â‰¤17years, confirming the high prevalence of comorbidities among patients with epilepsy across all ages" /><sentence text=" Despite the availability of numerous newer AEDs, older AEDs are still being frequently prescribed, especially for elderly patients, notably phenytoin"><entity charOffset="141-150" id="DDI-PubMed.28575767.s17.e0" text="phenytoin" /></sentence><sentence text=" This warrants careful consideration, given the strong propensity of enzyme-inducing AEDs to interact with other drugs, producing unwanted side effects" /><sentence text=" These results highlight the value of real-life prescription patterns and the potential in informing treatment decisions to ensure patients receive appropriate treatment" /><sentence text="" /></document>